Skip to content
Home/Companies/Biotech/Ruby Bio

Ruby Bio

Biotech·United States·Active·1yr hold
Entry
2025
Hold
1yr
Status
Active

Who owns Ruby Bio?

Ruby Bio is an American Biotech company, currently owned by Nucleus Capital since 2025.

Hand-verified · updated 2026-07-03

Open JSON · CC-BY
Nucleus Capital
Investor
Nucleus Capital
Nucleus Capital II · 2024 · VC

Key facts

HQUnited States
SectorBiotech
StatusActive

More from Nucleus Capital II

Other portfolio companies in the same fund.

Bindbridge
Bindbridge
Active
BiotechUK· 2026
Triple Bio
Triple Bio
Active
BiotechNetherlands· 2026
AtmoCooling
Active
ClimateTechUS· 2025
Spark E-Fuels
Active
ClimateTechGermany· 2025
Telura
Telura
Active
ClimateTechGermany· 2025
Apoha
Active
Deep TechUK· 2024

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns Ruby Bio?

Ruby Bio is currently owned by Nucleus Capital, through Nucleus Capital II, since 2025.

When did Nucleus Capital acquire Ruby Bio?

Nucleus Capital acquired Ruby Bio in 2025.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue